Advertisement
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
Document › Details
ProBioGen AG. (3/24/21). "Press Release: ProBioGen Enters into Agreement with Nobelpharma for Manufacturing Process Development of their Vaccine Project". Berlin.
![]() |
Organisation | ProBioGen AG |
Group | Minapharm (Group) | |
Organisation 2 | Nobelpharma Co., Ltd. | |
Group | Nobelpharma (Group) | |
![]() |
Product | AGE1.CR duck cell line |
Product 2 | vaccine | |
![]() |
Person | Schneider, Gabriele (ProBioGen 200309– Business Development) |
ProBioGen AG is delighted to announce the signing of a service agreement for Nobelpharma’s highly relevant vaccine project.
Earlier work confirmed already the versatility and benefit of ProBioGen’s vaccine development platform, consisting of the proprietary, well-proven AGE1.CR.pIX® suspension cell line and its high performance cell culture medium, for the propagation of Nobelpharma’s virus strain.
Now, ProBioGen applies state-of-the-art technologies and a deep expertise to perform the upstream and downstream process development for Nobelpharma's highly relevant vaccine for large scale manufacturing.
The duck cell line AGE1.CR.pIX was designed to serve the industrial, GMP-compliant production of a wide variety of viruses in large bioreactors and is free of any adventitious agents.
It has already proven its great utility for viral vector production in various clinical trials.
About ProBioGen
ProBioGen is a Contract Development and Manufacturing Organization (CDMO) and technology provider with extensive expertise in cell line engineering, process development and GMP manufacturing of biopharmaceuticals.
Our proprietary technologies like CHO.RiGHT®, the genetic glyco-engineering GlymaxX® and the targeted transposase DirectedLuck™ in combination with our efficient process development and robust GMP manufacturing accelerate and advance the development of drug candidates – from early concept to industrial market-readiness.
ProBioGen provides modern manufacturing solutions for viral vectors with its continuous AGE1.CR® duck cell line, a vaccine platform with MVA-CR19 and renders technology support in gene therapy and vaccine development.
All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen is successfully serving international clients for more than 26 years, is privately owned and based in Berlin.
Contact ProBioGen
Dr. Gabriele Schneider
Chief Business Officer
cmo@probiogen.de
+49 (0)30 3229 35 100
www.probiogen.de
Record changed: 2022-02-05 |
Advertisement
![Picture [iito] No Tracking 650x100px](/banner/iito-business-intelligence-20211013-650-100-summer-banner-series-no-tracking.jpg)
More documents for Minapharm (Group)
- [1] ProBioGen AG. (2/11/22). "Press Release: ProBioGen Signs a Commercial License Agreement with AstraZeneca Providing their GlymaxX® Technology". Berlin....
- [2] ProBioGen AG. (6/22/21). "Press Release: ProBioGen and Lava Therapeutics N.V. Sign Agreement for Cell Line Development for Manufacturing of a Novel Bispecific". Berlin & Utrecht....
- [3] ProBioGen AG. (10/22/20). "Press Release: Heidelberg Pharma Contracts ProBioGen for Cell Line Development and Manufacturing Services". Berlin....
- [4] ProBioGen AG. (4/28/20). "Press Release: ProBioGen AG Appoints Dr. Lutz Hilbrich as New Chief Executive Officer – Dr. Wieland Wolf Retires". Berlin & Cairo....
- [5] ProBioGen AG. (3/24/20). "Press Release: Immunogenesis Contracts ProBioGen for Development and Large-Scale Manufacturing Services". Berlin & Houston, TX....
- [6] ProBioGen AG. (2/25/20). "Press Release: ImmunOs Therapeutics Selects ProBioGen for Development and Large-Scale Manufacturing Services". Berlin & Schlieren....
- [7] ProBioGen AG. (1/14/20). "Press Release: ProBioGen and Lava Therapeutics Sign Cell Line Development and GMP Manufacturing Agreement for Novel Bispecific Molecule". Berlin & Utrecht....
- [8] ProBioGen AG. (1/8/20). "Press Release: ProBioGen Inks Next Commercial GlymaxX License with Roche. ADCC-enhancement for Innovative Cancer Therapy". Berlin....
- [9] ProBioGen AG. (11/12/19). "Press Release: DirectedLuck, a Transposase for Efficient Gene Delivery and High-Titer Cell Line Development". Berlin....
- [10] ProBioGen AG. (10/1/19). "Press Release: ProBioGen and Ceva Santé Animale Sign an Exclusive License Agreement to Produce Vectorised Poultry Vaccines Using AGE1.CR Production Technology". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top